睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由北京大学第三医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学第三医院Peking University Third Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07460362,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Diagnosis of MCL established by histologic assessment

    入选标准第 4 条

  3. Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography [CT] scan)

    入选标准第 9 条

    Measurable lesions on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), (GTD)≥1.5 cm

    入选标准第 12 条

  4. Combined with other malignant tumors within 3 years;

    排除标准第 4 条

    Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07460362,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. • Signed Informed Consent Forms
  2. Age: >= 18 to 80 years
  3. Eastern Cooperative Oncology Group =< 2
  4. Diagnosis of MCL established by histologic assessment
  5. Previously treated with at least one prior line of systemic therapy for mantle cell lymphoma.
  6. Prior therapy have included a BTK inhibitor, including ibrutinib, zanubrutinib, obrutinib, acalabrutinib and various BTKi in clinical trials. BTki exposure is required, which include BTKi failure or intolerance. BTKi failure is defined as progression of disease during BTKi therapy or patients have progressed or relapsed after completing BTK inhibitor therapy
  7. At least one high risk features as classified:
  8. Blastoid/pleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion
  9. Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography [CT] scan)
  10. Patients that did not achieve a CR with their first-line treatment
  11. early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines
  12. Measurable lesions on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), (GTD)≥1.5 cm
  13. Adequate liver function : Total bilirubin =< 3 x upper limit of normal (ULN) (unless has Gilbert's disease), Aspartate aminotransferase (AST) =< 5.0 x ULN, Alanine aminotransferase (ALT) =< 5.0 x ULN

排除标准:Exclusion Criteria:

  1. • Already enrolled in other Ongoing interventional or non-interventional R/R MCL clinical trials;
  2. Currently receiving immunosuppressive treatment for other diseases;
  3. Previous treatment with lenalidomide;
  4. Combined with other malignant tumors within 3 years;
  5. The researcher determines that they are not suitable to participate in this study;
  6. Serious mental or neurological disorders that affect informed consent and/or the expression or observation of adverse reactions;
  7. Have a history of major or extensive cardiovascular disease, such as New York Heart Association class III or Grade IV heart disease or objective assessment, myocardial infarction, unstable arrhythmia or unstable angina within 6 months before the first cycle;
  8. Recent major surgery (within 4 weeks before the start of the first cycle);
  9. Active autoimmune diseases with poor treatment control;
  10. Any active infection that may affect the safety of the participant, including bacterial, fungal and various viral infections, occurred within 7 days before the first day of cycle 1;
  11. Positive SARS-CoV-2 PCR test within 7 days prior to enrollment
  12. Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HBsAg] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.
  13. Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  14. A history of severe deep vein thrombosis event or pulmonary embolism within 6 months
  15. Patient follow-up was not possible.

引自 ClinicalTrials.gov, NCT07460362, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07460362,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07460362